# Cardiovascular Disease Risk
URL: https://genohealth.app/conditions/cardiovascular-disease
Type: Condition
Evidence: Strong evidence
Last reviewed: 2025-06-30

## Intro
Atherosclerotic cardiovascular disease (ASCVD) is the slow build-up of cholesterol-bearing plaque in artery walls. Risk is best understood as a combination of particle count (ApoB), cumulative exposure over decades, blood pressure, blood sugar, inflammation and genetic susceptibility — particularly APOE genotype and Lp(a).

## Summary
Heart disease is the leading cause of death globally — and one of the most modifiable conditions when biomarkers and genotype are read together.

## Key facts
- Top biomarkers: ApoB, LDL-C, Lp(a), hsCRP, A1c, blood pressure
- Key genes: APOE, LDLR, PCSK9, LPA
- Highest-leverage lever: Lifetime ApoB exposure

## Biomarker framework
- ApoB — counts atherogenic particles directly; target < 80 mg/dL general, < 60 mg/dL high-risk
- LDL-C — most studied lipid marker; target depends on overall risk
- Lp(a) — measure once in a lifetime; genetically set; > 50 mg/dL is independent risk
- hsCRP — inflammation marker that adds prognostic information
- Fasting glucose, A1c, blood pressure — independent risk multipliers

## Genetic context
- APOE ε4 — higher LDL, higher cardiovascular and Alzheimer's risk
- APOE ε2 — usually lower LDL but can cause type III hyperlipoproteinemia
- LDLR, APOB, PCSK9 — familial hypercholesterolemia (much higher lifetime risk)
- 9p21 region — modest but well-replicated risk locus

## What actually moves outcomes
- Lower lifetime ApoB exposure — diet, exercise, weight, and medication when needed
- Blood pressure < 130/80 in most adults
- Don't smoke; limit alcohol
- Cardio 150+ min/week plus resistance training
- Treat sleep apnea, diabetes, kidney disease aggressively

## Related (knowledge graph)

### Biomarkers
- ApoB (/biomarkers/apob): ApoB is the most discriminating single lipid marker for atherosclerotic CV risk. [Strong evidence]
- LDL-C (/biomarkers/ldl-cholesterol): Lowering LDL-C reduces major cardiovascular events proportionally to the reduction achieved. [Strong evidence]

### Genes
- APOE (/genes/apoe): APOE ε4 carriers run higher LDL and ApoB; ε2 carriers can develop type III hyperlipoproteinemia. [Strong evidence]

## FAQ
**Q: Should I get an Lp(a) test?**
A: Yes, once in your lifetime. Lp(a) is genetically determined and a strong independent risk factor — knowing your level changes how aggressively to manage the rest of your lipid profile.

**Q: Does APOE ε4 mean I'll get heart disease?**
A: No. It increases susceptibility but doesn't determine outcome. ε4 carriers benefit disproportionately from lipid-lowering, low-saturated-fat eating patterns and consistent exercise.

## Citations
- Sniderman et al., JAMA Cardiology 2019 (PMID 31389978): ApoB is a more discriminating marker of CV risk than LDL-C or non-HDL-C.
- ESC/EAS Guidelines 2019: ApoB and Lp(a) added to risk assessment alongside LDL-C.

Disclaimer: Informational only — not medical advice.